Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments
Heart failure is a common complication in patients with diabetes, and people with both conditions present a worse prognosis. Sodium– glucose cotransporter 2 inhibitors (SGLT2Is) increase urinary glucose excretion, improving glycaemic control. In type 2 diabetes (T2D), some SGLT2Is reduce major cardi...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2019-01-01
|
| Series: | European Cardiology Review |
| Online Access: | https://www.ecrjournal.com/articleindex/ecr.2018.34.2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846122567164755968 |
|---|---|
| author | Juan Tamargo |
| author_facet | Juan Tamargo |
| author_sort | Juan Tamargo |
| collection | DOAJ |
| description | Heart failure is a common complication in patients with diabetes, and people with both conditions present a worse prognosis. Sodium– glucose cotransporter 2 inhibitors (SGLT2Is) increase urinary glucose excretion, improving glycaemic control. In type 2 diabetes (T2D), some SGLT2Is reduce major cardiovascular events, heart failure hospitalisations and worsening of kidney function independent of glycaemic control. Multiple mechanisms (haemodynamic, metabolic, hormonal and direct cardiac/renal effects) have been proposed to explain these cardiorenal benefits. SGLT2Is are generally well tolerated, but can produce rare serious adverse effects, and the benefit/risk ratio differs between SGLT2Is. This article analyses the mechanisms underlying the cardiorenal benefits and adverse effects of SGLT2Is in patients with T2D and heart failure and outlines some questions to be answered in the near future. |
| format | Article |
| id | doaj-art-f82de07dc0f24218a4e62e82fdcb57e0 |
| institution | Kabale University |
| issn | 1758-3756 1758-3764 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | European Cardiology Review |
| spelling | doaj-art-f82de07dc0f24218a4e62e82fdcb57e02024-12-14T16:01:10ZengRadcliffe Medical MediaEuropean Cardiology Review1758-37561758-37642019-01-01141233210.15420/ecr.2018.34.2Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future DevelopmentsJuan Tamargo0Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, CIBERCV, Madrid, SpainHeart failure is a common complication in patients with diabetes, and people with both conditions present a worse prognosis. Sodium– glucose cotransporter 2 inhibitors (SGLT2Is) increase urinary glucose excretion, improving glycaemic control. In type 2 diabetes (T2D), some SGLT2Is reduce major cardiovascular events, heart failure hospitalisations and worsening of kidney function independent of glycaemic control. Multiple mechanisms (haemodynamic, metabolic, hormonal and direct cardiac/renal effects) have been proposed to explain these cardiorenal benefits. SGLT2Is are generally well tolerated, but can produce rare serious adverse effects, and the benefit/risk ratio differs between SGLT2Is. This article analyses the mechanisms underlying the cardiorenal benefits and adverse effects of SGLT2Is in patients with T2D and heart failure and outlines some questions to be answered in the near future.https://www.ecrjournal.com/articleindex/ecr.2018.34.2 |
| spellingShingle | Juan Tamargo Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments European Cardiology Review |
| title | Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments |
| title_full | Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments |
| title_fullStr | Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments |
| title_full_unstemmed | Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments |
| title_short | Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments |
| title_sort | sodium glucose cotransporter 2 inhibitors in heart failure potential mechanisms of action adverse effects and future developments |
| url | https://www.ecrjournal.com/articleindex/ecr.2018.34.2 |
| work_keys_str_mv | AT juantamargo sodiumglucosecotransporter2inhibitorsinheartfailurepotentialmechanismsofactionadverseeffectsandfuturedevelopments |